Ascentage Pharma Group International
OTC:ASPHF
Ascentage Pharma Group International
OTC:ASPHF
Price:
8.48
USD
Market Closed
Market Cap:
$2.7B
Balance Sheet
Balance Sheet Decomposition
Ascentage Pharma Group International
Ascentage Pharma Group International
Balance Sheet Decomposition is not available for
Ascentage Pharma Group International
Ascentage Pharma Group International
Balance Sheet
Ascentage Pharma Group International
Ascentage Pharma Group International
Currency: CNY
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
295
|
15
|
957
|
882
|
1 024
|
1 707
|
1 346
|
1 038
|
1 261
|
|
| Cash |
295
|
15
|
957
|
882
|
1 024
|
1 707
|
1 346
|
1 038
|
1 261
|
|
| Short-Term Investments |
157
|
384
|
14
|
0
|
0
|
0
|
130
|
31
|
343
|
|
| Total Receivables |
8
|
8
|
5
|
3
|
13
|
76
|
61
|
164
|
99
|
|
| Accounts Receivables |
1
|
0
|
0
|
0
|
0
|
54
|
54
|
146
|
83
|
|
| Other Receivables |
8
|
8
|
5
|
0
|
0
|
22
|
7
|
18
|
16
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
4
|
9
|
16
|
7
|
|
| Other Current Assets |
3
|
8
|
13
|
24
|
41
|
98
|
90
|
95
|
132
|
|
| Total Current Assets |
464
|
415
|
990
|
909
|
1 079
|
1 885
|
1 636
|
1 344
|
1 474
|
|
| PP&E Net |
5
|
25
|
67
|
142
|
477
|
844
|
649
|
957
|
906
|
|
| PP&E Gross |
5
|
25
|
67
|
142
|
477
|
844
|
649
|
957
|
906
|
|
| Accumulated Depreciation |
3
|
7
|
15
|
25
|
35
|
42
|
71
|
151
|
221
|
|
| Intangible Assets |
87
|
81
|
75
|
72
|
66
|
60
|
84
|
85
|
76
|
|
| Goodwill |
25
|
25
|
25
|
25
|
25
|
25
|
25
|
25
|
25
|
|
| Long-Term Investments |
13
|
30
|
60
|
32
|
32
|
28
|
374
|
19
|
34
|
|
| Other Long-Term Assets |
1
|
6
|
12
|
25
|
52
|
97
|
62
|
70
|
104
|
|
| Other Assets |
25
|
25
|
25
|
25
|
25
|
25
|
25
|
25
|
25
|
|
| Total Assets |
593
N/A
|
582
-2%
|
1 229
+111%
|
1 205
-2%
|
1 731
+44%
|
2 940
+70%
|
2 830
-4%
|
2 500
-12%
|
2 618
+5%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
0
|
4
|
5
|
13
|
23
|
71
|
96
|
72
|
92
|
|
| Accrued Liabilities |
21
|
28
|
47
|
90
|
61
|
75
|
121
|
126
|
153
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
140
|
120
|
290
|
|
| Current Portion of Long-Term Debt |
0
|
2
|
38
|
92
|
51
|
49
|
378
|
496
|
489
|
|
| Other Current Liabilities |
56
|
45
|
15
|
7
|
142
|
165
|
147
|
120
|
142
|
|
| Total Current Liabilities |
78
|
80
|
105
|
202
|
276
|
361
|
881
|
934
|
1 167
|
|
| Long-Term Debt |
0
|
3
|
2 080
|
9
|
479
|
1 035
|
1 274
|
1 179
|
889
|
|
| Deferred Income Tax |
22
|
20
|
19
|
17
|
15
|
14
|
12
|
11
|
5
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
10
|
|
| Other Liabilities |
508
|
611
|
37
|
86
|
114
|
296
|
254
|
306
|
282
|
|
| Total Liabilities |
608
N/A
|
713
+17%
|
2 241
+214%
|
315
-86%
|
884
+181%
|
1 705
+93%
|
2 422
+42%
|
2 440
+1%
|
2 354
-4%
|
|
| Equity | ||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
13
|
128
|
1 028
|
2 438
|
3 094
|
3 887
|
4 799
|
5 737
|
6 155
|
|
| Additional Paid In Capital |
0
|
0
|
44
|
3 454
|
4 130
|
5 342
|
5 393
|
5 951
|
6 545
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
27
|
21
|
0
|
|
| Other Equity |
2
|
4
|
27
|
126
|
189
|
221
|
159
|
133
|
126
|
|
| Total Equity |
15
N/A
|
132
-802%
|
1 012
-668%
|
890
N/A
|
847
-5%
|
1 235
+46%
|
409
-67%
|
60
-85%
|
264
+337%
|
|
| Total Liabilities & Equity |
593
N/A
|
582
-2%
|
1 229
+111%
|
1 205
-2%
|
1 731
+44%
|
2 940
+70%
|
2 830
-4%
|
2 500
-12%
|
2 618
+5%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
195
|
195
|
195
|
209
|
226
|
263
|
265
|
290
|
315
|
|
Switch to:
Switch to:
See Also
Discover More
